Trastuzumab should be considered cost effective in France

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.592, 2009-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Should Cost of Care be Considered in a Clinical Practice Guideline?

By Evans William K. Brouwers Melissa C. Bell Chaim M.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 224-226

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Etanercept considered cost effective vs DMARDs in RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 446, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Trastuzumab cost effective in HER2-positive breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Trastuzumab cost effective in HER2-positive breast cancer

Inpharma, Vol. 1, Iss. 1586, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Rotavirus vax should be "highly cost-effective" in Bolivia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 632, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite